111, Inc. (YI)

USD 8.4

(1.82%)

EBITDA Summary of 111, Inc.

111, Inc.'s latest annual EBITDA in 2023 was -311.26 Million CNY , up 12.09% from previous year.
111, Inc.'s latest quarterly EBITDA in 2024 Q2 was 5.61 Million CNY , down -2.21% from previous quarter.
111, Inc. reported an annual EBITDA of -330.18 Million CNY in 2022, up 42.55% from previous year.
111, Inc. reported an annual EBITDA of -614.91 Million CNY in 2021, down -33.12% from previous year.
111, Inc. reported a quarterly EBITDA of 5.56 Million CNY for 2024 Q1, up 102.72% from previous quarter.
111, Inc. reported a quarterly EBITDA of N/A for 2023 FY, up 12.09% from previous quarter.

Annual EBITDA Chart of 111, Inc. (2023 - 2016)

Historical Annual EBITDA of 111, Inc. (2023 - 2016)

Year	EBITDA	EBITDA Growth
2023	-311.26 Million CNY	12.09%
2022	-330.18 Million CNY	42.55%
2021	-614.91 Million CNY	-33.12%
2020	-459.29 Million CNY	4.93%
2019	-481.84 Million CNY	-26.89%
2018	-389.1 Million CNY	-66.48%
2017	-234.45 Million CNY	34.62%
2016	-350.63 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	5.61 Million CNY	-2.21%
2024 Q1	5.56 Million CNY	102.72%
2023 FY	- CNY	12.09%
2023 Q1	-16.71 Million CNY	83.78%
2023 Q2	-37.74 Million CNY	-125.79%
2023 Q3	-78.02 Million CNY	-106.69%
2023 Q4	-196.33 Million CNY	-151.64%
2022 FY	- CNY	42.55%
2022 Q2	-76.64 Million CNY	21.95%
2022 Q4	-103.06 Million CNY	-34.13%
2022 Q3	-76.84 Million CNY	-0.26%
2022 Q1	-98.19 Million CNY	3.41%
2021 Q1	-167.15 Million CNY	-18.57%
2021 FY	- CNY	-33.12%
2021 Q3	-164.54 Million CNY	10.63%
2021 Q4	-101.65 Million CNY	38.22%
2021 Q2	-184.11 Million CNY	-10.14%
2020 Q1	-112.85 Million CNY	30.39%
2020 Q3	-118.95 Million CNY	-30.66%
2020 Q4	-140.98 Million CNY	-18.52%
2020 FY	- CNY	4.93%
2020 Q2	-91.04 Million CNY	19.33%
2019 Q2	-97.46 Million CNY	6.98%
2019 FY	- CNY	-26.89%
2019 Q1	-104.77 Million CNY	16.6%
2019 Q4	-162.13 Million CNY	-44.11%
2019 Q3	-112.5 Million CNY	-15.44%
2018 Q2	-90.54 Million CNY	-125.0%
2018 Q4	-125.64 Million CNY	1.89%
2018 Q1	-40.24 Million CNY	37.08%
2018 Q3	-128.06 Million CNY	-41.44%
2018 FY	- CNY	-66.48%
2017 Q2	-57.62 Million CNY	1.62%
2017 FY	- CNY	34.62%
2017 Q4	-63.95 Million CNY	-2.98%
2017 Q1	-58.57 Million CNY	0.0%
2017 Q3	-62.1 Million CNY	-7.78%
2016 FY	- CNY	0.0%

Peer EBITDA Comparison of 111, Inc.

Name	EBITDA	EBITDA Difference
CannBioRx Life Sciences Corp.	-22.13 Million USD	-1306.256%
China Jo-Jo Drugstores, Inc.	1.22 Million USD	25470.85%
Harrow Health, Inc. 8.625% Senior Notes due 2026	9.72 Million USD	3301.286%
Harrow Health, Inc. 11.875% Senior Notes due 2027	9.72 Million USD	3301.286%
Leafly Holdings, Inc.	-5.73 Million USD	-5328.34%
LifeMD, Inc.	-8.21 Million USD	-3689.283%
LifeMD, Inc.	-8.21 Million USD	-3689.283%
TRxADE HEALTH, Inc.	-13.72 Million USD	-2168.576%
PetMed Express, Inc.	-394 Thousand USD	-78900.254%
Walgreens Boots Alliance, Inc.	-11.27 Billion USD	97.24%